Email Updates

You are here

The Science of Choice: The future of HIV prevention research

April 8, 2019

<em>Px Pulse</em> Logo

Earlier this year, the US Government’s National Institutes of Health (NIH) Division of AIDS (DAIDS) published its Funding Opportunity Announcement (FOA), signaling its priorities for the 2021-2027 funding cycle for HIV research. The US public sector is the largest global funder of HIV prevention research and the announcement has major implications for shaping the landscape of HIV research globally. Outlined in the FOA, DAIDS is looking to fund research that will advance antibodies, vaccines, multi-purpose technologies (MPTs) and antiretrovirals (ARVs) as prevention, as well as research on social and behavioral strategies, among other things.

In this episode of Px Pulse, hear DAIDS leader Carl Dieffenbach and colleague, Director Sheryl Zwerski address the position of non-systemic strategies of prevention at the January AIDS Research Advisory Committee meeting, where the priorities of the FOA were presented. (Non-systemic strategies such as topical microbicides do not provide protection throughout the body.) A major leader in HIV prevention science, South African researcher Linda-Gail Bekker talks about an ideal future pipeline, a research agenda she calls the “science of choice”. And AVAC’s Manju Chatani-Gada talks to two young women advocates from Zimbabwe who explain the limits of prevention today and why more choices will mean greater empowerment.

Maximina Jokonya is a mentor for Africaid and Audrey Nosenga works for Zimbabwe Young Positives.

Listen to the full podcast (24:01).


Additional Resources

Basic Info Pages